Pfizer Inc. (PFE)
Was Q2 The Turning Point For Pfizer Stock?
With Pfizer's sales rising in Q2, despite falling sales of Covid-19 products, we think that it may well be the turning point for Pfizer stock. It has seen a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs.
Pfizer, BioNtech say combined flu-COVID vaccine misses a main goal of Phase 3 trial
Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and they are evaluating next steps.
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
Novo Nordisk and Eli Lilly currently dominate the weight loss market thanks to their leading glucagon-like peptide-1 (GLP-1) receptor agonists. Their diabetes and obesity care medications are administered via injection.
Pfizer (PFE) Touts RSV Jab Benefit in Immunocompromised Adults
Results from a late-stage study show that Pfizer's (PFE) RSV vaccine generated strong neutralizing responses in immunocompromised adults after receiving a single dose.
Pfizer: Growing Beyond Covid
Pfizer continues to transition to a strong future with reduced Covid drug sales. The biopharma has a strong lineup of new drugs whether via FDA approval or acquisition. The stock has a large dividend yield of 5.9%.
Pfizer data points to strong efficacy, particularly most at-risk groups
Pfizer Inc (NYSE:PFE, ETR:PFE) looks set to open higher Monday after it revealed that its late-stage trial for a Respiratory Syncytial Virus (RSV) vaccine showed strong neutralizing responses after a single dose in adults. The Phase 3 study tested Abrysvo against a placebo in people with immunocompromising conditions at risk for severe RSV-related lower respiratory tract disease.
Pfizer reports positive results in trial of vaccine for immunocompromised adults at risk of severe RSV-related illness
Pfizer Inc. PFE, -0.73% said Monday a substudy of a Phase 3 trial of a treatment for immunocompromised adults aged 18 and older at risk of developing severe respiratory syncytial virus-associated lower respiratory track disease achieved positive safety and immunogenicity results. The trial is evaluating two doses of the drug company's Abrysvo vaccine in treatment adults at increased risk of developing RSV-LTRD, Pfizer said in a statement.
Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study
Pfizer said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and older with a compromised immune system.
Is Pfizer Stock a Buy Now After Earnings?
Pfizer posted positive growth during the second quarter, a heartening sign for shareholders. Strong demand for several products beyond its COVID-19 portfolio supports a positive outlook.
Forget Tech! 3 Value Stocks That Could Win Big From Rate Cuts.
Investors usually rush into tech stocks when rate cuts loom on the horizon, as they do now. Federal Reserve Chair Jerome Powell just said that those cuts could come in September.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
3 Cheap Stocks to Buy in August for Under $50
Finding the right stocks for investment can be a tricky game. While there are thousands of stocks to choose from, only a few can pass the test of time.
